In the diabetes TRIUMPH-2 trial, reported side effects included: Diarrhea (around 27 to 34 percent of participants, depending on the dose) Nausea (14 to 28 percent) Constipation (14 to 17 percent) Decreased appetite (6 to 17 percent) Vomiting (6 to 16 percent) In the TRIUMPH-3 trial for adults with severe obesity and heart disease, participants reported: Diarrhea (around 24 to 30 percent of participants, depending on the dose) Nausea (22 percent) Constipation (16 to 18 percent) Decreased appetite (14 to 15 percent) Hyperglycemia, or high blood sugar (3 to 4 percent) The high rates of diarrhea surprised Ali
As new findings emerge, they will guide adjustments in clinical practices, potentially setting new standards in the treatment of complex diseases such as diabetes, autoimmune disorders, and beyond
Its very important to adhere to the monitoring plan
Claire Meek, a consultant in the diabetes in pregnancy service at Addenbrookes Hospital and principal investigator at the Institute of Metabolic Science at the University of Cambridge in the U.K., to explore how GLP-1s affect oral birth control
Patients with diabetic retinopathy should have regular ophthalmologic monitoring
The FDA's Position on Compounded Semaglutide The FDA removed semaglutide from its drug shortage list in February 2024
,aspect=ignore)
